Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorders

Apr 6, 2021

Phase 1 clinical study investigates safety and tolerability, pharmacokinetics and pharmacodynamic effects of first-in-class azasugar AZ-3102 in healthy subjects AZ-3102 is being initially developed for the treatment of patients suffering from GM1 and GM2...

How large pharma impacts biotechnology startup success – Nature Biotechnology

Feb 16, 2021

BGV's Daniela Couto and Gina Melcher von Dydiowa together with Sander van Deventer of Forbion published an article in Nature Biotechnology on pharma involvement in biotech startup success. Click on this link to read the whole article. Abstract: Many novel therapeutic...

Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman

Feb 2, 2021

Philippe Dro brings entrepreneurial expertise and biotech, medtech and pharma industry experience Successful serial entrepreneur with track record of growing companies, notably for Themis and Glycovaxyn Joins at a key juncture in Scenic Biotech’s strategic growth,...

CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer

Jan 28, 2021

Munich, Germany, January 28, 2021 — CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced today the start of clinical development of CTL-002, its proprietary GDF-15 neutralizing antibody designed to enhance effector T cell entry...

News overview

Next events

BioEquity 17-19 May 2021

Apr 6, 2021

The BGV team shall attend the Bio-Equity 2021 online conference. Partnering can be scheduled through the online platform. https://conferences.biocentury.com/bioequity-europe-2021

Event overview